The key catalyst is Week 28 EVERLAST-A data at end-Q3 2026, which will indicate durability of the 63.5% PASI 100 response at Week 16. Positive durability data supporting once- to twice-yearly dosing could re-rate the stock. Watch for Q4 2026 EVERLAST-B Phase 2b data to inform Phase 3 dose selection and registration path.
Price Chart
Executive Summary
Oruka Therapeutics reported Q2 2026 net loss of $41.2M ($0.55/share) vs $0.49 consensus, a 12.2% beat on EPS. Revenue is zero as this is a pre-commercial biotech. The company's cash position grew to $1.1B following an upsized $700M public offering in April 2026, providing runway through a planned BLA filing for ORKA-001. Pipeline catalysts include Week 28 EVERLAST-A data expected end-Q3 2026, Week 16 EVERLAST-B data in Q4 2026, and Phase 3 initiation for ORKA-001 in 1H 2027.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $41.2M, compared to $24.6M in Q2 2025
- EPS of $-0.55 vs consensus $-0.49 (12.2% beat)
- Cash, cash equivalents, and marketable securities of $1.1B as of June 30, 2026
- Cash runway expected to fund operations through a BLA filing for ORKA-001
- April 2026 upsized $700M public offering completed
- EVERLAST-A Week 28 data expected end-Q3 2026; 52-week data in December 2026
- EVERLAST-B fully enrolled (187 subjects) ahead of schedule; Week 16 data in Q4 2026
- Phase 3 program for ORKA-001 expected to begin in 1H 2027
- ORCA-SURGE Week 16 data accelerated to Q1 2027
- ORCA-SPLASH Phase 2 trial in hidradenitis suppurativa initiated
- ORKA-004 (TL1A antibody) to enter the clinic in Q4 2026
- May 2026 amendment to IL-23 license with Paragon expanded to include IBD
- R&D expenses $43.3M in Q2 2026 vs $24.1M in Q2 2025
Financial Impact
Net loss widened to $41.2M from $24.6M YoY, as R&D burn increased 80% with pipeline expansion. Cash position strengthened to $1.1B after $700M offering, funding into BLA filing.
Risk Factors
- Clinical failure risk: EVERLAST-A/B or ORCA-SURGE data could disappoint on efficacy or durability
- Dilution from $700M April offering overhang — share count increased significantly
- Pre-revenue biotech with no approved products; full dependence on pipeline execution
- Competitive IL-23p17 and IL-17A/F space with established products from J&J, AbbVie, UCB, Novartis
- R&D spend rising rapidly ($43.3M/quarter) — cash burn rate may accelerate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-086933 |
| Document: ea0301312-8k_oruka.htm | 0001213900-26-086933 |
| Document: 0001213900-26-086933-index-headers.html | 0001213900-26-086933 |
| Document: 0001213900-26-086933-index.html | 0001213900-26-086933 |
| Document: 0001213900-26-086933.txt | 0001213900-26-086933 |
| 8-K Data (Synthetic) | 0001213900-26-086933 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | Insider Cluster | $93.55 $89.93 | ▼ −3.87% | ▼ −6.44% | $84.38 (−9.80%) |
Sep 1, 2026 4w ago | Insider Cluster | $91.63 $91.65 | ▼ −0.02% | ▼ −0.98% | $84.38 (+7.91%) |
Aug 28, 2026 5w ago | EFFECT | $91.15 $92.51 | ▼ −1.50% | ▼ −1.39% | $84.38 (+7.42%) |
Aug 17, 2026 6w ago | Insider Cluster | $113.08 $101.82 | ▼ −9.96% | ▼ −9.76% | $84.38 (−25.38%) |
Aug 10, 2026 7w ago | Press Release | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 10, 2026 7w ago | 8-K | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 9, 2026 7w ago | Institutional Cluster | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Jul 15, 2026 11w ago | Insider Cluster | $83.04 $91.95 | ▲ +10.73% | ▲ +12.40% | $84.38 (+1.61%) |
Jul 2, 2026 13w ago | Insider Cluster | $85.21 $88.27 | ▲ +3.59% | ▲ +2.66% | $84.38 (−0.97%) |
Jun 22, 2026 14w ago | Insider Cluster | $83.40 $92.49 | ▲ +10.90% | ▲ +9.89% | $84.38 (+1.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access